If you’ve struggled with depression that hasn’t responded to traditional treatment, Spravato™ (esketamine nasal spray) offers a new path forward. FDA-approved and backed by clinical research, this innovative treatment works rapidly—often within hours—to relieve symptoms of major depressive disorder (MDD) and treatment-resistant depression (TRD).
Spravato™ is a groundbreaking, FDA-approved treatment designed for individuals battling major depressive disorder and treatment-resistant depression. Research has shown its ability to rapidly ease depressive symptoms—regardless of age, background, or the root cause of the condition. Whether your depression stems from trauma, hormonal shifts, postpartum changes, or life challenges, Spravato™ offers renewed hope. It’s helping people who haven’t responded to traditional medications, with many experiencing significant relief and even remission. At Oasis Behavioral Health, we believe this treatment can be your turning point toward brighter days.
Spravato Dosing for Treatment-Resistant Depression
Patient Resources
Patient Resources
Spravato benefits investigation form
Personalized Treatment Protocols & Insurance Guidance
Spravato™ treatment follows FDA-recommended dosing: typically twice weekly for the first month, then weekly or biweekly depending on your response. Many insurance providers now cover Spravato™, and our experienced insurance coordinators will help you navigate the preauthorization process with ease. We’re here to simplify the steps so you can focus on your mental wellness.
If you’re a visual learner, we also offer easy-to-understand visuals during your consultation to help explain the treatment timeline.
Ready to begin your journey?
